# A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

> **NCT04926324** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Iowa** · enrollment: 3 (actual)

## Conditions studied

- Rectal Neoplasms
- Rectal Neoplasm Malignant

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Dostarlimab
- **RADIATION:** Short course radiation

## Key facts

- **NCT ID:** NCT04926324
- **Lead sponsor:** University of Iowa
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-07
- **Primary completion:** 2024-11-18
- **Final completion:** 2024-12-26
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor terminated
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04926324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04926324, "A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04926324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*